How the interaction occurs:
Your antibiotic can affect your heart's rhythm. Other drugs can have the same effect.
What might happen:
Taking your antibiotic with other agents that can affect your heart rhythm may increase your risk of irregular heartbeat, which may be life-threatening.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to perform an electrocardiogram (ECG) on you to check your heart's rhythm. Let your doctor know right away if you notice an irregular heartbeat or have any dizziness or fainting episodes.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.
2.Uroxatral (alfuzosin hydrochloride) US prescribing information. Sanofi-Synthelabo, Inc. May, 2013.
3.Apokyn (apomorphine hydrochloride) US prescribing information. Tercica, Inc. July, 2010.
4.Foradil Aerolizer (formoterol fumarate) US prescribing information. Schering Corporation September, 2012.
5.Tequin (gatifloxacin) US prescribing information. Bristol-Myers Squibb Company January, 2006.
6.Factive (gemifloxacin mesylate) US prescribing information. Oscient Pharmaceuticals August, 2013.
7.NegGram (nalidixic acid) US prescribing information. Sanofi-Synthelabo, Inc. November, 2012.
8.Noroxin (norfloxacin) US prescribing information. Merck & Co., Inc. August, 2013.
9.Votrient (pazopanib) US prescribing information. GlaxoSmithKline June, 2014.
10.Noxafil (posaconazole) UK summary of product characteristics. Schering-Plough Ltd. February 2, 2006.
11.Edurant (rilpivirine) US prescribing information. Tibotec Pharmaceuticals June, 2013.
12.Ultane (sevoflurane) US prescribing information. AbbVie, Inc. February, 2014.
13.Lexapro (escitalopram oxalate) US prescribing information. Forest Pharmaceuticals Inc. December, 2012.
14.USFood and Drug Administration. FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm March 28, 2012.
15.Health Canada. Antidepressant Cipralex (escitalopram): Updated information regarding dose-related heart risk. Available at: http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2012/136 74a-eng.php May 7, 2012.
16.Cipralex (escitalopram oxalate) Canadian prescribing information. Lundbeck August 13, 2012.
17.Cipralex (escitalopram oxalate) UK summary of product characteristics. Lunbeck Limited September 14, 2012.
18.Gilenya (fingolimod) US prescribing information. Novartis Pharmaceuticals Corporation April, 2014.
19.MHRA United Kingdom. Fingolimod (Gilenya): transient bradycardias and heart block after first dose - strengthened cardiovascular monitoring. Drug Safety Update Feb 2012;5(7):A1.
20.Cipro (ciprofloxacin hydrochloride) US prescribing information. Bayer Corporation August, 2013.
21.Ciproxin (ciprofloxacin hydrochloride) UK summary of product characteristics. Bayer plc April 13, 2010.
22.Primovist (gadoxetate disodium) Australian prescribing information. Schering-Plough Corporation November 1, 2005.
23.Primovist (gadoxetic acid) UK summary of product characteristics. Bayer plc May 1, 2008.
24.Istodax (romidepsin) US prescribing information. Celgene Corporation June, 2013.
25.The University of Arizona Center for Education and Research of Therapeutics. Drugs with Risk of Torsades de Pointes and Drugs with Possible Risk of Torsades de Pointes. Available at:http://www.crediblemeds.org/. Updated March 14, 2013.
26.Phansalkar S, Desai AA, Bell D, Yoshida E, Doole J, Czochanski M, Middleton B, Bates DW. High-priority drug-drug interactions for use in electronic health records. J Am Med Inform Assoc 2012 Sep-Oct; 19(5):735-43.